Method for in-vitro preparation of double-layered virus-like particles of rotavirus

Patent metadata

Field	Value
Publication number	US-9862933-B2
Application number	US-201314429586-A
Country	US
Kind code	B2
Filing date	Jun 24, 2013
Priority date	Sep 20, 2012
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.

First claim

What is claimed is:

1. A method for preparing a double-layered virus-like particle of rotavirus comprising rotavirus VP2 protein and VP6 protein, the method comprising the following steps of:
a) expressing VP6 in a soluble form in a prokaryotic expression system, and purifying the VP6, wherein the purified VP6 protein retains its native conformation and is present in a form of trimer; and
b) co-assembling the purified VP6 with VP2 extracellularly, and with VP2 in a non-particulate state, to form a double-layered particle 2/6-VLP.

2. The method according to claim 1 , wherein the VP6 protein is prepared by the following steps of:
1) expressing a rotavirus VP6 protein in E. coli;
2) to lysis supernatant comprising the VP6 protein, adding polyethylene imine (PEI) or an analog thereof, or a divalent or trivalent metal ion, to precipitate nucleic acids and some undesired proteins, wherein the concentration of PEI is between 0.05% and 0.2%, the metal ion includes Mn 2+ , Mg 2+ , Ca 2+ , Zn 2+ and Al 3+ , when used, the concentration of Ca 2+ is between 10 and 80 mM;
3) performing centrifugation, and subjecting the lysis supernatant to salting-out and chromatographic purification.

3. The method according to claim 2 , wherein the salting-out is performed using saturated ammonium sulfate.

4. The method according to claim 3 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between 3.0 and 7.0;
c) the assembly buffer contains 0-2M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:1 and 1:10.

5. The method according to claim 4 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between pH 4.0 and pH 6.4;
c) the assembly buffer contains 150 mM-2 M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:2 and 1:3.

6. The method according to claim 1 , wherein the VP2 protein is VP2 protein in a non-particulate state prepared by the following steps:
1) expressing rotavirus VP2 protein in E. coli;
2) adding polyethyleneimine (PEI) to lysis supernatant containing the VP2 protein, wherein the concentration of PEI is between 0.05% and 1%;
3) performing centrifugation, and purifying the lysis supernatant by salting-out and chromatography.

7. The method according to claim 6 , wherein the salting-out is performed using ammonium sulfate.

8. The method according to claim 7 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between 3.0 and 7.0;
c) the assembly buffer contains 0-2M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:1 and 1:10.

9. The method according to claim 8 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between pH 4.0 and pH 6.4;
c) the assembly buffer contains 150 mM-2 M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:2 and 1:3.

10. The method according to claim 1 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between 3.0 and 7.0;
c) the assembly buffer contains 0-2M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:1 and 1:10.

11. The method according to claim 10 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between pH 4.0 and pH 6.4;
c) the assembly buffer contains 150 mM-2 M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:2 and 1:3.

12. The method according to claim 2 , wherein the chromatography includes hydrophobic interaction chromatography and ion exchange chromatography.

13. The method according to claim 12 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between 3.0 and 7.0;
c) the assembly buffer contains 0-2M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:1 and 1:10.

14. The method according to claim 13 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between pH 4.0 and pH 6.4;
c) the assembly buffer contains 150 mM-2 M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:2 and 1:3.

15. The method according to claim 12 , wherein the chromatography is chromatography by Phenyl HP (GE) under the condition of 3M NaCl, wherein nucleic acids pass through the column, VP6 protein is eluted under the condition of 2M NaCl, and the undesired protein is eluted under the condition of no salts.

16. The method according to claim 2 , wherein the assembly of the double-layered virus-like particle 2/6-VLP comprises, mixing VP6 and VP2 proteins, then replacing the buffer with an assembly buffer to form a double-layered virus-like particle, wherein:
a) VP2 and VP6 are purified proteins which are not assembled into particles and have a purity of above 95%;
b) the assembly buffer is a phosphate buffer, a MES buffer or a citrate buffer, with a pH of between 3.0 and 7.0;
c) the assembly buffer contains 0-2M NaCl; and
d) the ratio of VP2 and VP6 by mass is between 1:1

Assignees

• Univ Xiamen
• Xiamen Innovax Biotech Co Ltd

Inventors

• Ge Shengxiang
• Li Tingdong
• Guo Qingshun
• Xu Feihai
• Zhang Jun
• Xia Ningshao

Classifications

• C12N2720/12323

  Virus like particles [VLP] · CPC title

• C12N2720/12333

  Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K38/162 Primary

  from virus · CPC title

• C12N2720/12334

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title